GIP/GLP-1 Dual Receptor Agonist
Tirzepatide
Dual GIP and GLP-1 receptor agonist studied for superior metabolic regulation, glucose homeostasis, and body weight reduction in preclinical models.
Select Size
Tested by: Intertek Pharmaceutical Services · Batch: VRC-TIR-2406 · Jun 2026
About Tirzepatide
Tirzepatide is a novel dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism has demonstrated enhanced glycemic control and weight reduction compared to single-receptor agonists in preclinical and clinical research. It is used as a research tool in type 2 diabetes, obesity, and metabolic syndrome models.
Research Areas
Technical Specifications
Molecular Weight
4813.48 g/mol
Amino Acid Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Gly-Lys(C20 diacid)-Gly-NH₂
Storage
Lyophilized: −20°C, stable 24 months. Reconstituted: 4°C, use within 28 days.
Solubility
Soluble in 10mM PBS pH 7.4 at ≥1 mg/mL
For Research Purposes Only. Tirzepatide is sold exclusively for in vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use. See our Research Use Disclaimer.